Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonist medications have transformed weight loss treatment globally, with semaglutide becoming one of the most prescribed medications in the United States. Recent data shows that prescription volumes for semaglutide have increased more than tenfold since 2021, reflecting both clinical efficacy and growing public awareness. PlexusDx provides access to compounded semaglutide injection through licensed 503A pharmacies, helping patients across all 50 states access this therapy without insurance requirements.

Current Statistics on Semaglutide and GLP-1 Medication Usage

Approximately 4.1 million Americans had filled at least one prescription for semaglutide or tirzepatide by 2024, representing a significant expansion from 2021 when usage was minimal. The spike reflects both FDA approvals for weight loss indications and increased prescriber confidence in the safety profile of GLP-1 therapies. Insurance claims data and pharmacy fill rates consistently show upward trends, with demand outpacing supply in many regions during peak periods.

Among GLP-1 medications, semaglutide accounts for a substantial share of total prescriptions, competing primarily with tirzepatide and older incretin-based drugs. Demographic analysis reveals that women represent approximately 60–70% of weight loss medication users, and the average age of semaglutide patients spans 30 to 65 years. Geographic variation exists, with urban and suburban areas showing higher adoption rates than rural regions, partly due to healthcare access differences.

Why Semaglutide Prescriptions Have Surged in Recent Years

The FDA approval of semaglutide (Wegovy) for chronic weight management in 2021 removed previous limitations and expanded the eligible patient population dramatically. Media coverage, celebrity endorsements, and positive clinical trial results accelerated public interest and patient demand. Healthcare providers also became more comfortable prescribing GLP-1 medications as safety databases expanded and long-term outcome studies demonstrated cardiovascular and metabolic benefits beyond weight loss alone.

Supply chain challenges and insurance coverage barriers initially slowed adoption despite high demand. Compounded versions from licensed 503A pharmacies emerged as a critical alternative, allowing patients to access semaglutide therapy affordably without insurance or membership fees. PlexusDx compounded semaglutide injection starts at $149 per month across all commitment tiers, making evidence-based weight loss medication accessible to a broader population.

Demographics of GLP-1 Users: Who Is Taking Semaglutide?

Semaglutide users span diverse age groups, with the largest populations in adults aged 35–60. However, younger adults (25–34) represent a growing segment, driven by increased body image awareness and metabolic health focus. Patients with type 2 diabetes or prediabetes initially formed the largest user group, but those seeking weight loss without diabetes now represent the majority of new prescriptions.

Socioeconomic factors influence access, with higher-income populations historically achieving faster adoption due to affordability and insurance coverage. PlexusDx addresses this disparity by offering HSA and FSA eligibility alongside direct-pay pricing, ensuring patients across income levels can afford treatment. Men comprise approximately 30–40% of semaglutide users, though engagement campaigns specifically targeting men have increased enrollment in recent years.

Personalized Treatment Options: Beyond Standard Semaglutide Therapy

While semaglutide remains the most prescribed GLP-1 monotherapy, individual patient response varies significantly based on genetic factors, metabolic pathways, and concurrent health conditions. The Precision Peptide Genetic Test from PlexusDx analyzes key genetic variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 to map 14 metabolic pathways and 150+ personalized insights. This precision approach helps identify which patients may benefit most from semaglutide versus tirzepatide or dual-compound protocols.

PlexusDx also offers GLP-Squared Injection, a dual-compound combining semaglutide and tirzepatide, starting at $249 per month for patients requiring enhanced GLP-1 and GIP receptor activation. Oral formulations of semaglutide and tirzepatide provide alternatives for needle-averse patients, with oral semaglutide beginning at $249 monthly. The Microdose GLP-1 Protocol at $129 monthly serves patients seeking conservative dosing to minimize gastrointestinal side effects while maintaining therapeutic benefit.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How many people in the United States are currently taking Ozempic or semaglutide for weight loss?

Approximately 4.1 million Americans have filled semaglutide or tirzepatide prescriptions as of 2024, with semaglutide representing the majority of GLP-1 fills. The number continues to grow monthly as awareness increases and compounded options improve affordability. PlexusDx serves patients across all 50 states seeking compounded semaglutide injection at $149 per month without insurance requirements.

What clinical evidence supports the use of semaglutide for weight loss?

The STEP trials demonstrated that semaglutide produces 15–22% body weight reduction over 68 weeks compared to 2.6% with placebo, with sustained effects at follow-up. Cardiovascular outcome data shows benefits beyond weight loss, including reduced heart attack and stroke risk in patients with existing cardiovascular disease. The GLP-1 receptor mechanism works by enhancing satiety signaling in the brain while slowing gastric emptying, making sustained calorie restriction more achievable.

Is PlexusDx compounded semaglutide as effective as brand-name Ozempic or Wegovy?

PlexusDx obtains all compounded semaglutide from licensed 503A pharmacies under strict quality controls, ensuring bioavailability and potency matching pharmaceutical standards. The active compound is identical; difference lies in formulation method and cost. Patients typically achieve comparable weight loss and metabolic improvements on compounded semaglutide starting at $149 per month compared to higher brand-name costs.

What are the most common side effects of semaglutide therapy?

Gastrointestinal symptoms—including nausea, vomiting, diarrhea, and constipation—occur in 20–50% of patients, typically mild and transient during dose escalation. Some patients experience fatigue or decreased appetite beyond the intended appetite suppression. PlexusDx offers the Microdose GLP-1 Protocol at $129 monthly for patients who experience side effects at standard dosing, allowing slower titration while maintaining therapeutic benefit.

Can the PlexusDx Precision Peptide Genetic Test help predict my response to semaglutide?

Yes. The Precision Peptide Genetic Test (available at $99 after your first month of treatment) analyzes variants in GLP1R and other peptide pathways to identify your genetic predisposition for GLP-1 responsiveness. This test maps 14 metabolic pathways and 150+ insights, helping PlexusDx personalize your therapy—whether semaglutide monotherapy, tirzepatide, or dual-compound protocols best suit your biology.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves